Biogen (BIIB) Change in Intangibles (2011 - 2025)
Biogen (BIIB) posted quarterly Change in Intangibles of $16.3 million for Q4 2025, up 8.67% year-over-year from $15.0 million in Q4 2024, and up 207.55% on a QoQ basis from $5.3 million in Q3 2025.
Biogen (BIIB) Change in Intangibles (2011 - 2025) Analysis & Trends
Biogen (BIIB) has reported Change in Intangibles for 14 consecutive years, with $16.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Intangibles rose 8.67% year-over-year to $16.3 million; the TTM figure through Mar 2026 stood at $21.6 million (down 83.27% YoY), while the FY2025 annual figure was $31.6 million, down 84.67% from the prior year.
- Change in Intangibles came in at $16.3 million for Q4 2025 at Biogen, up from $5.3 million in the prior quarter.
- The five-year high for Change in Intangibles was $95.0 million in Q3 2024, with the low at $1.0 million in Q4 2022.
- Average Change in Intangibles over 5 years is $20.1 million, with a median of $11.7 million recorded in 2023.
- Across the five-year window, Change in Intangibles surged 1400.0% in 2024 and plunged 94.42% in 2025, its largest moves.
- Year by year, Change in Intangibles stood at $16.9 million in 2021, then slumped by 94.08% to $1.0 million in 2022, then soared by 1240.0% to $13.4 million in 2023, then gained by 11.94% to $15.0 million in 2024, then increased by 8.67% to $16.3 million in 2025.
- According to Business Quant data, Change in Intangibles over the past three periods registered $16.3 million, $5.3 million, and $10.0 million for Q4 2025, Q3 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -991.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -461.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.30 Mn |
| Dec 31, 2025 | 16.30 Mn |
| Sep 30, 2025 | 5.30 Mn |
| Sep 30, 2025 | 5.30 Mn |
| Mar 31, 2025 | 10.00 Mn |
| Mar 31, 2025 | 10.00 Mn |
| Dec 31, 2024 | 15.00 Mn |
| Dec 31, 2024 | 15.00 Mn |
| Sep 30, 2024 | 95.00 Mn |
| Sep 30, 2024 | 95.00 Mn |
| Jun 30, 2024 | 9.10 Mn |
| Jun 30, 2024 | 9.10 Mn |
| Mar 31, 2024 | 75.00 Mn |
| Mar 31, 2024 | 75.00 Mn |
| Sep 30, 2023 | 13.40 Mn |
| Sep 30, 2023 | 13.40 Mn |
| Jun 30, 2023 | 16.00 Mn |
| Jun 30, 2023 | 16.00 Mn |
| Mar 31, 2023 | 5.00 Mn |
| Mar 31, 2023 | 5.00 Mn |